Star Imaging and Path Lab has issued its FY26 annual report and a corrigendum rectifying typographical errors in test volume data and earnings per share figures. The company confirmed its 22nd AGM for September 29, 2026, while reporting a steady rise in consolidated profit after tax to ₹19.26 crore.
Star Imaging FY26 Annual Report and Corrigendum Overview
Profit After Tax: ₹19.26 Crore; Revenue from Operations: ₹88.53 Crore.
Reader Takeaway: Steady profit growth provides comfort, though minor clerical errors in financial reporting require investor diligence.
What just happened
Star Imaging and Path Lab Limited has released its annual report for the financial year ended March 31, 2026, alongside a formal corrigendum. The company corrected a significant typographical error where "tests conducted" was inaccurately listed as 7.1 million instead of 0.71 million. Additionally, the company adjusted its Basic and Diluted EPS figures to ₹12.20 for FY26 and ₹11.82 for FY25 and confirmed the 22nd Annual General Meeting will take place on September 29, 2026.
Why this matters
The corrigendum highlights the need for precision in statutory filings, though the underlying financial performance remains positive. With consolidated revenue from operations rising to ₹88.53 crore from ₹83.50 crore in the previous year, the company continues to demonstrate stable growth. Investors now have the corrected data points necessary to evaluate the company's financial health ahead of the upcoming shareholder meeting.
Business and Operational Overview
Star Imaging maintains a network of 24 diagnostic centres spanning three states. The firm utilizes a hybrid business model targeting B2G, B2B, and B2C segments. Strategic priorities include geographic expansion into tier-II and tier-III cities, the integration of pathology services into existing radiology centres, and investments in molecular diagnostics and genomics.
Risks to watch
Investors should closely monitor the execution of the company's capital expenditure plans for new centre additions. The healthcare diagnostic sector is highly sensitive to regulatory compliance and potential delays in operationalizing new facilities, which could impact projected growth timelines.
What to track next
The 22nd AGM on September 29, 2026, will be the next key touchpoint for shareholders to engage with management regarding long-term scaling efforts and the impact of the newly adopted infrastructure investments.